Method for production of neutrophils and uses therefor

• US 20040076617A1
• Filed: 03/18/2003
• Published: 04/22/2004
• Est. Priority Date: 03/18/2002
• Status: Abandoned Application

• Current Assignee: National Jewish Medical and Research Center
• Original Assignee: National Jewish Medical and Research Center
• Inventors: Worthen, George Scott, Lieber, Jonathan Gregory, Keller, Gordon M., Webb, Saiphone
• Application Number:
  US10/394,508
• Publication Number:
  US 20040076617A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/155 Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
• CPC Class Codes: C12N 2501/22 Colony stimulating factors (G-CSF, GM-CSF)
• CPC Class Codes: C12N 2501/23 Interleukins [IL]
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 2510/00 Genetically modified cells
• CPC Class Codes: C12N 5/0642 Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells

Abstract

An in vitro method for the differentiation of functionally mature neutrophils from stem cells is disclosed. Also disclosed are methods of producing genetically modified neutrophils in vitro and methods of using the neutrophils produced according to the invention.

Claims

1. A method for producing neutrophils in vitro, comprising:

a) providing an expanded population of neutrophil progenitor cells;

b) culturing the expanded population of neutrophil progenitor cells with semi-confluent stromal cells in a medium suitable for culture of animal cells, the medium comprising at least one interleukin-6 (IL-6) family cytokine, to produce a secondary differentiation culture; and

c) culturing the cells from the secondary differentiation culture of step (b) with semi-confluent stromal cells in a medium suitable for culture of animal cells, the medium comprising;

granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF) and at least one IL-6 family cytokine, to produce functionally mature neutrophils.

2. The method of claim 1, wherein step (a) comprises culturing stem cells in a liquid medium in the absence of stromal cells to produce an expanded population of neutrophil progenitor cells.

3. The method of claim 2, wherein the stem cells are embryonic stem cells.

4. The method of claim 1, wherein the neutrophil progenitor cells are day 8 or day 9 embryoid body (EB) hematopoietic precursor cells.

5. The method of claim 4, wherein the EB hematopoietic precursor cells are day 8 EB hematopoietic precursor cells.

6. The method of claim 4, wherein the EB hematopoietic precursor cells are produced by a method comprising culturing embryonic stem cells for 8-9 days in a medium suitable for the culture of animal cells comprising platelet-depleted or preselected animal serum, wherein the medium does not comprise leukemia inhibitory factor (LIF).

7. The method of claim 4, the EB hematopoietic precursor cells are produced by a method comprising culturing embryonic stem cells for 8-9 days in a medium suitable for the culture of animal cells comprising:

platelet-depleted or preselected animal serum, L-glutamine, a protein-free hybridoma medium, ascorbic acid, and monothiolglycerol (MTG), and wherein the medium does not comprise leukemia inhibitory factor (LIF).

8. The method of claim 1, wherein the stromal cells in (b) or (c) do not produce macrophage colony stimulating factor (M-CSF).

9. The method of claim 1, where the stromal cells in (b) or (c) are cultured with an agent that binds to and blocks or inactivates M-CSF.

10. The method of claim 9, wherein the agent is selected from the group consisting of a soluble receptor for M-CSF and an antibody that selectively binds to M-CSF.

11. The method of claim 1, wherein the IL-6 family cytokine in step (b) comprises at least one cytokine selected from the group consisting of:

interleukin-6 (IL-6), interleukin-11 (IL-11), oncostatin M (OSM), and leukemia inhibitory factor (LIF).

12. The method of claim 1, wherein the medium of step (b) further comprises at least one growth factor selected from the group consisting of:

basic fibroblast growth factor (bFGF) and c-kit ligand (KL) supernate.

13. The method of claim 1, wherein the medium of step (b) comprises:

IL-6, bFGF, KL supernate, IL-11, and LIF.

14. The method of claim 1, wherein the medium of step (b) comprises:

a base medium suitable for culture of animal cells, platelet-depleted or preselected animal serum, MTG, OSM, bFGF, IL-11, IL-6, KL supernate, and LIF.

15. The method of claim 1, wherein the medium of step (b) comprises:

a base medium suitable for the culture of myeloid cells, platelet-depleted or preselected animal serum, OSM, bFGF, IL-11, IL-6, KL supernate, and LIF.

16. The method of claim 1, wherein the medium of step (b) comprises:

a base medium suitable for the culture of animal cells, L-glutamine, 2-mercaptoethanol, folic acid, i Inositol, platelet-depleted or preselected animal serum, OSM, bFGF, IL-11, IL-6, KL supernate, and LIF.

17. The method of claim 1, wherein the medium in step (b) comprises hydrocortisone.

18. The method of claim 17, wherein the hydrocortisone is 21-hemisuccinate sodium salt.

19. The method of claim 1, wherein step (b) of culturing is performed for between about 2 days and about 6 days.

20. The method of claim 1, wherein step (b) of culturing is performed for between about 2 days and about 4 days.

21. The method of claim 1, wherein step (b) of culturing is performed for about 6 days.

22. The method of claim 1, wherein step (b) of culturing comprises, at about 24 hours after beginning the culturing of step (b), additional steps of:

i) harvesting cells in suspension;

ii) de-adhering the stromal cells and adherent hematopoietic precursors;

iii) replating the de-adhered stromal cells and de-adhered adherent hematopoietic precursors from step (ii) onto tissue culture plates for about 20-45 minutes; and

iv) adding cells that remain in suspension after step (iii) to the harvested cells of step (i) for continued culture according to step (b).

23. The method of claim 1, further comprising an additional replating step between step (b) and step (c) comprising:

i) harvesting cells in suspension;

ii) de-adhering the stromal cells and adherent hematopoietic precursors;

iii) replating the de-adhered stromal cells and de-adhered adherent hematopoietic precursors from step (ii) onto tissue culture plates for about 20-45 minutes; and

iv) adding cells that remain in suspension after step (iii) to the harvested cells of step (i) for the step of culturing according to step (c).

24. The method of claim 1, wherein the IL-6 family cytokine in step (c) comprises at least one cytokine selected from the group consisting of:

interleukin-6 (IL-6), interleukin-11 (IL-11), oncostatin M (OSM), and leukemia inhibitory factor (LIF).

25. The method of claim 1, wherein the medium of step (c) comprises:

a base medium suitable for culture of animal cells, platelet-depleted or preselected animal serum, L-glutamine, MTG, G-CSF, GM-CSF and IL-6.

26. The method of claim 1, wherein the medium of step (c) comprises:

a base medium suitable for the culture of myeloid cells, platelet-depleted or preselected animal serum, L-glutamine, G-CSF, GM-CSF, and IL-6.

27. The method of claim 1, wherein the medium of step (c) comprises:

a base medium suitable for the culture of animal cells, L-glutamine, 2-mercaptoethanol, folic acid, i Inositol, platelet-depleted or preselected animal serum, G-CSF, GM-CSF, and IL-6.

28. The method of claim 1, wherein the medium in step (c) comprises hydrocortisone.

30. The method of claim 1, wherein step (c) is performed for at least about 5 days.

31. The method of claim 1, wherein step (c) is performed for between about 5 days and about 15 days.

32. The method of claim 1, wherein steps (b) and (c) of culturing are in a liquid culture medium.

33. The method of claim 1, wherein step (b) or step (c) of culturing is performed at about 37°

C.

34. The method of claim 1, wherein step (b) or step (c) of culturing is performed at between about 30°

C. and 37°

C.

35. The method of claim 1, wherein step (b) or step (c) of culturing is performed at about 33°

C.

36. The method of claim 1, wherein step (b) or step (c) of culturing is performed at about 20% oxygen.

37. The method of claim 1, wherein step (b) or step (c) of culturing is performed at less than about 20% oxygen.

38. The method of claim 1, wherein step (b) or step (c) of culturing is performed at less than about 10% oxygen.

39. The method of claim 1, wherein step (b) or step (c) of culturing is performed at about 5% oxygen.

40. The method of claim 1, further comprising, after step (c) of culturing has been performed for at least about 5 to about 7 days, an additional step of adding to the culture in step (c) cells selected from the group consisting of:

an expanded population of neutrophil progenitor cells and cells produced in step (b) of the method, to provide extended production of functionally mature neutrophils by the method.

41. The method of claim 1, wherein the cells provided in step (a) are genetically modified.

42. The method of claim 41, wherein the genetic modification comprises transfection of stem cells used to derive the cells in step (a) with a recombinant nucleic acid molecule encoding a heterologous protein.

43. The method of claim 41, wherein stem cells used to derive the cells in step (a) are genetically modified by deletion or inactivation of at least one gene in the cells.

44. The method of claim 41, wherein stem cells used to derive the cells in step (a) are genetically modified to increase or initiate the expression of at least one gene in the cells.

46. An isolated, genetically modified neutrophil produced by the method of claim 1.

47. A method for increasing the number of neutrophils in a patient by administering to the patient neutrophils produced by the method of claim 1.

48. The method of claim 47, wherein the patient has neutropenia.

49. The method of claim 47, wherein the patient'"'"'s endogenous neutrophils are functionally defective.

50. The method of claim 49, wherein the patient has an impairment of neutrophil function selected from the group consisting of:

a neutrophil granule deficiency, impaired neutrophil migration and a neutrophil receptor deficiency.

51. The method of claim 47, wherein the patient has a leukemia.

53. A method for regulating neutrophil activity in a patient by administering to the patient genetically modified neutrophils according to claim 46.

29. The method of claim 29, wherein the hydrocortisone is 21-hemisuccinate sodium salt.

45. An isolated, genetically modified neutrophil, wherein the neutrophil is produced in vitro.

52. A method for regulating neutrophil activity in a patient by administering to the patient genetically modified neutrophils according to claim 45.